RE: Royalties28 Apr 2020 15:19
well as I understand it the initial partnership is a collaberation and a joint development of the test, not just Avacta supplying Affimer reagents ... as worded via RNS:
"Partnership to develop and manufacture a rapid test for the COVID-19 coronavirus infection for population screening"
"The companies will develop and manufacture an Affimer-based point-of-care rapid test intended for screening of large populations to diagnose the COVID-19 coronavirus infection."
"Avacta is already generating Affimer reagents that detect the COVID-19 virus and together with Cytiva will develop and manufacture a test capable of diagnosing the infection in minutes"
"in only four weeks and well ahead of schedule, it has successfully generated multiple Affimer reagents that bind the SARS-COV-2 viral antigen as part of the collaboration with Cytiva"
"Avacta owns the intellectual property relating to the SARS-COV-2 Affimer reagents and retains all commercial rights."
"Avacta is in active discussion with other global diagnostic companies to develop Affimer-based COVID-19 antigen tests to increase high-throughput testing capacity on a world-wide scale."